TBB is a cell-permeable benzotriazolo compound that acts as a highly selective ATP/GTP-competitive protein kinase inhibitor. It has been shown to specifically inhibit casein kinase IIα (CK2α) and dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (Dyrk1A). TBB's strong binding action appears to result from both hydrophobic and van der Walls interactions. Other kinases such as GSK (glycogen synthase kinase), Cdk2 (CDK2) and phosphorylase kinase were inhibited to a lesser extent. TBB has also been shown to inhibit NS3-associated viral helicase activities in hepatitis C virus and West Nile virus. TBB has been used as an apoptotic inducer in Jerkat cells.
1. Fromageot, H P., et al., 1977. Adsorption of human erythrocyte surface glycoprotein onto polystyrene latex spheres. The Journal of laboratory and clinical medicine. 90(2): 324-9. PMID: 886218
2. Sarno, S., et al., 2001. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS letters. 496(1): 44-8. PMID: 11343704
3. Ruzzene, Maria., et al., 2002. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. The Biochemical journal. 364(Pt 1): 41-7. PMID: 11988074
4. Borowski, Peter., et al., 2003. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. European journal of biochemistry / FEBS. 270(8): 1645-53. PMID: 12694177
5. Zień, Piotr., et al., 2003. Selectivity of 4,5,6,7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources. Biochemical and biophysical research communications. 306(1): 129-33. PMID: 12788077
6. Sarno, Stefania., et al., 2003. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). The Biochemical journal. 374(Pt 3): 639-46. PMID: 12816539
7. Duncan, James S., et al., 2008. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Molecular & cellular proteomics : MCP. 7(6): 1077-88. PMID: 18258654
See how others have used TBB. Click on the entry to view the PubMed entry .
PMID: # 27033073 Misticone, S. et al. 2016. Methods in molecular biology (Clifton, N.J.). 1388: 95-110.
PMID: # 27693634 Wang, Y. et al. 2016. Cancer Lett. 383: 1-8.
PMID: # 24576828 Kho, DH. et al. 2014. Cancer Res. 74: 2229-37.
PMID: # 23333831 Chuang, KA. et al. 2013. Life sciences. 92: 677-86.
PMID: # 18467326 McDonnell, MA. et al. 2008. J. Biol. Chem. 283: 20149-20158.
PMID: # 18308722 Bachhuber, T. et al. 2008. J. Biol. Chem. 283: 13225-13232.
PMID: # 17289674 Treharne, KJ. et al. 2007. J. Biol. Chem. 282: 10804-10813.
PMID: # 16188887 Remus, D. et al. 2005. J. Biol. Chem. 280: 39740-39751.
PMID: # 15824109 Lolkema, MP. et al. 2005. J. Biol. Chem. 280: 22205-22211.
PMID: # 15159401 Russo, GL. et al. 2004. J. Biol. Chem. 279: 33012-33023.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.